{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:42:28Z","timestamp":1784569348729,"version":"3.55.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40257-026-01008-3","type":"journal-article","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T06:42:58Z","timestamp":1770532978000},"page":"227-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States"],"prefix":"10.1007","volume":"27","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-0474","authenticated-orcid":false,"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-0252","authenticated-orcid":false,"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaDe","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein-Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Ehst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6107-5282","authenticated-orcid":false,"given":"Wendy Smith","family":"Begolka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-8308","authenticated-orcid":false,"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-399X","authenticated-orcid":false,"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,8]]},"reference":[{"key":"1008_CR1","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(24)01810-5","volume":"404","author":"S Weidinger","year":"2024","unstructured":"Weidinger S, Novak N. Hand eczema. Lancet. 2024;404:2476\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(24)01810-5.","journal-title":"Lancet"},{"key":"1008_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/cod.13804","volume":"84","author":"AS Quaade","year":"2021","unstructured":"Quaade AS, Simonsen AB, Halling A, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population\u2014a systematic review and meta\u2010analysis. Contact Dermatitis. 2021;84:361\u201374. https:\/\/doi.org\/10.1111\/cod.13804.","journal-title":"Contact Dermatitis"},{"key":"1008_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00890-z","author":"E Weisshaar","year":"2024","unstructured":"Weisshaar E. Chronic hand eczema. Am J Clin Dermatol. 2024. https:\/\/doi.org\/10.1007\/s40257-024-00890-z.","journal-title":"Am J Clin Dermatol"},{"key":"1008_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/cod.14035","volume":"86","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova-Fischer I, Arents BWM, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86:357\u201378. https:\/\/doi.org\/10.1111\/cod.14035.","journal-title":"Contact Dermatitis"},{"key":"1008_CR5","first-page":"19","volume":"8","author":"D Dibenedetti","year":"2015","unstructured":"Dibenedetti D, Baranowski E, Zelt S, Reynolds M, Sherrill B. Assessing United States patient and dermatologist experiences with severe chronic hand eczema. J Clin Aesthet Dermatol. 2015;8:19\u201327.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1008_CR6","unstructured":"Smith T. Survey suggests lack of awareness, treatments for chronic hand eczema  [Internet]. HCP Live. 2025  [cited 2025 Apr 2]. https:\/\/www.hcplive.com\/view\/survey-suggests-lack-awareness-treatments-for-chronic-hand-eczema. Accessed 2 Apr 2025."},{"key":"1008_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4103\/ijd.ijd_281_21","volume":"66","author":"ZH Ahmed","year":"2021","unstructured":"Ahmed ZH, Agarwal K, Sarkar R. Hand dermatitis: a comprehensive review with special emphasis on COVID-19 pandemic. Indian J Dermatol. 2021;66:508\u201319. https:\/\/doi.org\/10.4103\/ijd.ijd_281_21.","journal-title":"Indian J Dermatol"},{"key":"1008_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12325-019-01164-5","volume":"37","author":"L Grant","year":"2020","unstructured":"Grant L, Seiding Larsen L, Burrows K, Belsito VD, Weisshaar E, Diepgen T, et al. Development of a conceptual model of chronic hand eczema (CHE) based on qualitative interviews with patients and expert dermatologists. Adv Ther. 2020;37:692\u2013706. https:\/\/doi.org\/10.1007\/s12325-019-01164-5.","journal-title":"Adv Ther"},{"key":"1008_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175741","volume":"12","author":"A Zalewski","year":"2023","unstructured":"Zalewski A, Krajewski PK, Szepietowski JC. Psychosocial consequences of hand eczema\u2014a prospective cross-sectional study. J Clin Med. 2023;12:5741. https:\/\/doi.org\/10.3390\/jcm12175741.","journal-title":"J Clin Med"},{"key":"1008_CR10","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.360","volume":"102","author":"W Jamil","year":"2022","unstructured":"Jamil W, Svensson \u00c5, Josefson A, Lindberg M, Von Kobyletzki L. Incidence rate of hand eczema in different occupations: a systematic review and meta-analysis. Acta Derm Venereol. 2022;102:adv00681. https:\/\/doi.org\/10.2340\/actadv.v102.360.","journal-title":"Acta Derm Venereol"},{"key":"1008_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40257-021-00669-6","volume":"23","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Hahn-Pedersen J, Bartlett C, Glanville J, Thyssen JP. Economic burden of chronic hand eczema: a review. Am J Clin Dermatol. 2022;23:287\u2013300. https:\/\/doi.org\/10.1007\/s40257-021-00669-6.","journal-title":"Am J Clin Dermatol"},{"key":"1008_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/idoj.IDOJ_782_20","volume":"13","author":"S Adabala","year":"2022","unstructured":"Adabala S, Doshi B, Manjunathswamy B. A cross-sectional study to assess the role of dermoscopy in differentiating palmar psoriasis, chronic hand eczema, and eczema in psoriatico. Indian Dermatol Online J. 2022;13:78. https:\/\/doi.org\/10.4103\/idoj.IDOJ_782_20.","journal-title":"Indian Dermatol Online J"},{"key":"1008_CR13","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2021.33.4.351","volume":"33","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Bang CH, Kim HO, Lee DH, Ko JY, Park EJ, et al. 2020 Korean consensus guidelines for diagnosis and treatment of chronic hand eczema. Ann Dermatol. 2021;33:351. https:\/\/doi.org\/10.5021\/ad.2021.33.4.351.","journal-title":"Ann Dermatol"},{"key":"1008_CR14","doi-asserted-by":"publisher","DOI":"10.5070\/D331164978","author":"J Burshtein","year":"2025","unstructured":"Burshtein J, Chovatiya R, Golant A, Zakria D, Shah M, Lio P, et al. Risks of topical corticosteroid therapy and role for advanced targeted topical treatments for inflammatory skin diseases: an expert consensus panel. Dermatol Online J. 2025. https:\/\/doi.org\/10.5070\/D331164978.","journal-title":"Dermatol Online J"},{"key":"1008_CR15","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1046\/j.1365-2133.1999.02819.x","volume":"140","author":"NK Veien","year":"1999","unstructured":"Veien NK, \u00d8lholm Larsen P, Thestrup-Pedersen K, Schou G. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol. 1999;140:882\u20136. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.02819.x.","journal-title":"Br J Dermatol"},{"key":"1008_CR16","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2147\/TCRM.S292504","volume":"16","author":"C Dubin","year":"2020","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges. Ther Clin Risk Manag. 2020;16:1319\u201332. https:\/\/doi.org\/10.2147\/TCRM.S292504.","journal-title":"Ther Clin Risk Manag"},{"key":"1008_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdin.2023.11.004","volume":"14","author":"A Egeberg","year":"2023","unstructured":"Egeberg A, Schlapbach C, Haugaard JH, Nymand L, Thein D, Thomsen SF, et al. Adverse events from topical corticosteroid use in chronic hand eczema\u2014findings from the Danish Skin Cohort. JAAD Int. 2023;14:77\u201383. https:\/\/doi.org\/10.1016\/j.jdin.2023.11.004.","journal-title":"JAAD Int."},{"key":"1008_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/DER.0000000000000659","volume":"32","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Guttman-Yassky E, Agner T, Bissonnette R, Cohen DE, Simpson E, et al. Chronic Hand Eczema Guidelines from an expert panel of the international eczema council. Dermatitis  [Internet]. 2021;32:319\u201326. https:\/\/doi.org\/10.1097\/DER.0000000000000659.","journal-title":"Dermatitis [Internet]"},{"key":"1008_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.048","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Agner T, Molin S, Guttman-Yassky E. Hand eczema. Part 1: epidemiology, pathogenesis, diagnosis and work-up. J Am Acad Dermatol  [Internet]. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.048.","journal-title":"J Am Acad Dermatol [Internet]"},{"key":"1008_CR20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2024","unstructured":"Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE\u2013 and Institute of Medicine\u2013based recommendations. Ann Allergy Asthma Immunol. 2024;132:274\u2013312. https:\/\/doi.org\/10.1016\/j.anai.2023.11.009.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1008_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010362","volume":"25","author":"V Tancredi","year":"2023","unstructured":"Tancredi V, Buononato D, Caccavale S, Di Brizzi EV, Di Caprio R, Argenziano G, et al. New perspectives in the management of chronic hand eczema: lessons from pathogenesis. Int J Mol Sci. 2023;25:362. https:\/\/doi.org\/10.3390\/ijms25010362.","journal-title":"Int J Mol Sci"},{"key":"1008_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2340\/00015555-1632","volume":"94","author":"C Apfelbacher","year":"2014","unstructured":"Apfelbacher C, Molin S, Weisshaar E, Bauer A, Elsner P, Mahler V, et al. Characteristics and provision of care in patients with chronic hand eczema: updated data from the CARPE registry. Acta Derm Venereol. 2014;94:163\u20137. https:\/\/doi.org\/10.2340\/00015555-1632.","journal-title":"Acta Derm Venereol"},{"key":"1008_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.0105-1873.2003.00159.x","volume":"49","author":"P Susitaival","year":"2003","unstructured":"Susitaival P, Flyvholm AM, Meding B, Kanerva L, Lindberg M, Svensson \u00c5, et al. Nordic occupational skin questionnaire (NOSQ\u20102002): a new tool for surveying occupational skin diseases and exposure. Contact Dermatitis. 2003;49:70\u20136. https:\/\/doi.org\/10.1111\/j.0105-1873.2003.00159.x.","journal-title":"Contact Dermatitis"},{"key":"1008_CR24","unstructured":"Det Nationale Forskningscenter for Arbejdsmilj\u00f8. English version of NOSQ-2002  [Internet].  [cited 2025 Apr 2]. https:\/\/nfa.dk\/vaerktoejer\/spoergeskemaer\/nordisk-spoergeskema-for-arbejdsbetingede-hudlidelser-nosq-2002\/engelsk-udgave-af-nosq-2002\/. Accessed 2 Apr 2025."},{"key":"1008_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.adengl.2019.12.007","volume":"111","author":"JFS Salvador","year":"2020","unstructured":"Salvador JFS, Mendaza FH, Garc\u00e9s MH, Palacios-Mart\u00ednez D, Camacho RS, Sanz RS, et al. Guidelines for the diagnosis, treatment, and prevention of hand eczema. Actas Dermo-Sifiliogr\u00e1ficas (English Edition). 2020;111:26\u201340. https:\/\/doi.org\/10.1016\/j.adengl.2019.12.007.","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"1008_CR26","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/ddg.15179","volume":"21","author":"A Bauer","year":"2023","unstructured":"Bauer A, Brans R, Brehler R, B\u00fcttner M, Dickel H, Elsner P, et al. S2k guideline diagnosis, prevention, and therapy of hand eczema. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 2023;21:1054\u201374. https:\/\/doi.org\/10.1111\/ddg.15179.","journal-title":"JDDG Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"1008_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-02818-3","volume":"316","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Agner T, Baranowski K, Plohberger U, Thoning H, Arbuckle R, et al. Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA\u2013CHE): a new clinician reported outcome measure of CHE severity. Arch Dermatol Res. 2024;316:110. https:\/\/doi.org\/10.1007\/s00403-024-02818-3.","journal-title":"Arch Dermatol Res"},{"key":"1008_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1365-2133.2004.06305.x","volume":"152","author":"E Held","year":"2005","unstructured":"Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability. Br J Dermatol. 2005;152:302\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2004.06305.x.","journal-title":"Br J Dermatol"},{"key":"1008_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/cod.13212","volume":"80","author":"H R\u00f6nsch","year":"2019","unstructured":"R\u00f6nsch H, Apfelbacher C, Brans R, Matterne U, Molin S, Ofenloch R, et al. Which outcomes have been measured in hand eczema trials? A systematic review. Contact Dermatitis. 2019;80:201\u20137. https:\/\/doi.org\/10.1111\/cod.13212.","journal-title":"Contact Dermatitis"},{"key":"1008_CR30","unstructured":"Topal Y. HECSI Score  [Internet]. 2025  [cited 2025 Jan 7]. https:\/\/hecsiscore.com\/. Accessed 7 Jan 2025."},{"key":"1008_CR31","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1111\/jdv.20140","volume":"38","author":"M Siewertsen","year":"2024","unstructured":"Siewertsen M, N\u00e4slund\u2010Koch C, Duus\u00a0Johansen J, Simonsen AB, Nguyen TT, Zachariae C, et al. Psychological burden, anxiety, depression and quality of life in patients with hand eczema: a systematic review and meta\u2010analysis. J Eur Acad Dermatol Venereol. 2024;38:2110\u20137. https:\/\/doi.org\/10.1111\/jdv.20140.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1008_CR32","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41591-024-02827-9","volume":"30","author":"OL Aiyegbusi","year":"2024","unstructured":"Aiyegbusi OL, Cruz Rivera S, Roydhouse J, Kamudoni P, Alder Y, Anderson N, et al. Recommendations to address respondent burden associated with patient-reported outcome assessment. Nat Med Nature Research. 2024;30:650\u20139. https:\/\/doi.org\/10.1038\/s41591-024-02827-9.","journal-title":"Nat Med. Nature Research"},{"key":"1008_CR33","unstructured":"CHORD Foundation. HECOS: Hand eczema core outcome set  [Internet]. 2025  [cited 2025 Jun 3]. https:\/\/www.c3outcomes.org\/hecos. Accessed 3 Jun 2025."},{"key":"1008_CR34","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1365-2133.2008.08487.x","volume":"158","author":"T Ruzicka","year":"2008","unstructured":"Ruzicka T, Lynde CW, Jemec GBE, Diepgen T, Berth-Jones J, Coenraads PJ, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158:808\u201317. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08487.x.","journal-title":"Br J Dermatol"},{"key":"1008_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.0105-1873.2006.00871.x","volume":"55","author":"C Skudlik","year":"2006","unstructured":"Skudlik C, Dulon M, Pohrt U, Appl KC, John SM, Nienhaus A. Osnabrueck hand eczema severity index \u2013 a study of the interobserver reliability of a scoring system assessing skin diseases of the hands. Contact Dermatitis. 2006;55:42\u20137. https:\/\/doi.org\/10.1111\/j.0105-1873.2006.00871.x.","journal-title":"Contact Dermatitis"},{"key":"1008_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2340\/00015555-2521","volume":"97","author":"A Carlsson","year":"2017","unstructured":"Carlsson A, Svensson \u0139, Anderson C, Baranovskaya I, Hinds\u00e9n-Stenstr\u00f6m M, Holt I, et al. Scoring of hand eczema: good reliability of Hand Eczema Extent Score (HEES). Acta Dermato-Venereol. 2017;97:193\u20137. https:\/\/doi.org\/10.2340\/00015555-2521.","journal-title":"Acta Dermato-Venereol"},{"key":"1008_CR37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"key":"1008_CR38","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s13555-024-01267-0","volume":"14","author":"E Weisshaar","year":"2024","unstructured":"Weisshaar E, Y\u00fcksel YT, Agner T, Larsen LS, Grant L, Arbuckle R, et al. Development and validation of a patient-reported outcome measure of the impact of chronic hand eczema on health-related quality of life: the Hand Eczema Impact Scale (HEIS). Dermatol Ther (Heidelb). 2024;14:3047\u201370. https:\/\/doi.org\/10.1007\/s13555-024-01267-0.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1008_CR39","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s13555-024-01114-2","volume":"14","author":"S Molin","year":"2024","unstructured":"Molin S, Larsen LS, Joensson P, Oesterdal ML, Arbuckle R, Grant L, et al. Development and psychometric validation of a patient-reported outcome measure to assess the signs and symptoms of chronic hand eczema: the Hand Eczema Symptom Diary (HESD). Dermatol Ther (Heidelb). 2024;14:643\u201369. https:\/\/doi.org\/10.1007\/s13555-024-01114-2.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1008_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-021-01877-8","volume":"19","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, et al. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021;19:247. https:\/\/doi.org\/10.1186\/s12955-021-01877-8.","journal-title":"Health Qual Life Outcomes"},{"key":"1008_CR41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.12819","volume":"171","author":"RF Ofenloch","year":"2014","unstructured":"Ofenloch RF, Weisshaar E, Dumke A-K, Molin S, Diepgen TL, Apfelbacher C. The quality of life in hand eczema questionnaire (QOLHEQ): validation of the German version of a new disease-specific measure of quality of life for patients with hand eczema. Br J Dermatol. 2014;171:304\u201312. https:\/\/doi.org\/10.1111\/bjd.12819.","journal-title":"Br J Dermatol"},{"key":"1008_CR42","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s13555-021-00543-7","volume":"11","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, de Bruin-Weller M, Bansal A, Chen Z, Nelson L, Whalley D, et al. Definition of clinically meaningful within-patient changes in POEM and CDLQI in children 6 to 11 years of age with severe atopic dermatitis. Dermatol Ther. 2021;11:1415\u201322. https:\/\/doi.org\/10.1007\/s13555-021-00543-7.","journal-title":"Dermatol Ther"},{"key":"1008_CR43","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/cod.13192","volume":"80","author":"JAF Oosterhaven","year":"2019","unstructured":"Oosterhaven JAF, Uter W, Aberer W, Armario\u2010Hita JC, Ballmer\u2010Weber BK, Bauer A, et al. European surveillance system on contact allergies (ESSCA): contact allergies in relation to body sites in patients with allergic contact dermatitis. Contact Dermatitis. 2019;80:263\u201372. https:\/\/doi.org\/10.1111\/cod.13192.","journal-title":"Contact Dermatitis"},{"key":"1008_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cod.12432","volume":"73","author":"JD Johansen","year":"2015","unstructured":"Johansen JD, Aalto\u2010Korte K, Agner T, Andersen KE, Bircher A, Bruze M, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing\u2014recommendations on best practice. Contact Dermatitis. 2015;73:195\u2013221. https:\/\/doi.org\/10.1111\/cod.12432.","journal-title":"Contact Dermatitis"},{"key":"1008_CR45","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/j.jaip.2024.05.035","volume":"12","author":"L Yin","year":"2024","unstructured":"Yin L, Ungar B, Guttman-Yassky E, Cohen DE, Karagounis TK. Beyond avoidance: advanced therapies for contact dermatitis. J Allergy Clin Immunol Pract. 2024;12:2260\u20137. https:\/\/doi.org\/10.1016\/j.jaip.2024.05.035.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1008_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/ACI.0000000000000621","volume":"20","author":"A Barbaud","year":"2020","unstructured":"Barbaud A. Mechanism and diagnosis of protein contact dermatitis. Curr Opin Allergy Clin Immunol. 2020;20:117\u201321. https:\/\/doi.org\/10.1097\/ACI.0000000000000621.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1008_CR47","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1053\/j.semdp.2016.12.017","volume":"34","author":"AA Gru","year":"2017","unstructured":"Gru AA. Introduction to inflammatory dermatoses: histological clues for the practicing pathologist. Semin Diagn Pathol. 2017;34:210\u20139. https:\/\/doi.org\/10.1053\/j.semdp.2016.12.017.","journal-title":"Semin Diagn Pathol"},{"key":"1008_CR48","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/jdv.20023","volume":"38","author":"M Tauber","year":"2024","unstructured":"Tauber M, Vocanson M. Biomarkers for chronic hand eczema: could etiological and clinical subtypes truly be the starting point? An open question. J Eur Acad Dermatol Venereol. 2024;38:997\u20138. https:\/\/doi.org\/10.1111\/jdv.20023.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1008_CR49","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1111\/jdv.13308","volume":"29","author":"T Agner","year":"2015","unstructured":"Agner T, Aalto\u2010Korte K, Andersen KE, Foti C, Gimen\u00e9z\u2010Arnau A, Goncalo M, et al. Classification of hand eczema. J Eur Acad Dermatol Venereol. 2015;29:2417\u201322. https:\/\/doi.org\/10.1111\/jdv.13308.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1008_CR50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40257-015-0130-z","volume":"16","author":"D Antonov","year":"2015","unstructured":"Antonov D, Schliemann S, Elsner P. Hand dermatitis: a review of clinical features, prevention and treatment. Am J Clin Dermatol. 2015;16:257\u201370. https:\/\/doi.org\/10.1007\/s40257-015-0130-z.","journal-title":"Am J Clin Dermatol"},{"key":"1008_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/cod.14775","author":"D Pesqu\u00e9","year":"2025","unstructured":"Pesqu\u00e9 D, Silvestre\u2010Salvador JF, Figueiredo AC, Pujol RM, Gon\u00e7alo M, Gim\u00e9nez\u2010Arnau AM. A review of hand eczema subtypes: clinical features, biomarkers and treatment strategies. Contact Dermatitis. 2025. https:\/\/doi.org\/10.1111\/cod.14775.","journal-title":"Contact Dermatitis"},{"key":"1008_CR52","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.27985","volume":"104","author":"A Glenn Ullum","year":"2024","unstructured":"Glenn Ullum A, Barati Sedeh F, Jemec GBE, Ibler KS. Professional cleaners\u2019 and healthcare workers\u2019 ability to recognize hand eczema. Acta Derm Venereol. 2024;104:adv27985. https:\/\/doi.org\/10.2340\/actadv.v104.27985.","journal-title":"Acta Derm Venereol"},{"key":"1008_CR53","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/cod.14020","volume":"86","author":"MM Sloot","year":"2022","unstructured":"Sloot MM, Loman L, Romeijn GLE, Rosenberg FM, Arents BWM, Schuttelaar MLA. Patients\u2019 perspectives on quality of care for chronic hand eczema: a qualitative study. Contact Dermatitis. 2022;86:204\u201312. https:\/\/doi.org\/10.1111\/cod.14020.","journal-title":"Contact Dermatitis"},{"key":"1008_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/jdv.16062","volume":"34","author":"P Elsner","year":"2020","unstructured":"Elsner P, Agner T. Hand eczema: treatment. J Eur Acad Dermatol Venereol. 2020;34:13\u201321. https:\/\/doi.org\/10.1111\/jdv.16062.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1008_CR55","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/cod.12860","volume":"78","author":"M Crepy","year":"2018","unstructured":"Crepy M, Lecuen J, Ratour\u2010Bigot C, Stocks J, Bensefa\u2010Colas L. Accelerator\u2010free gloves as alternatives in cases of glove allergy in healthcare workers. Contact Dermatitis. 2018;78:28\u201332. https:\/\/doi.org\/10.1111\/cod.12860.","journal-title":"Contact Dermatitis"},{"key":"1008_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/495917","volume":"2012","author":"RM Walters","year":"2012","unstructured":"Walters RM, Mao G, Gunn ET, Hornby S. Cleansing formulations that respect skin barrier integrity. Dermatol Res Pract. 2012;2012:1\u20139. https:\/\/doi.org\/10.1155\/2012\/495917.","journal-title":"Dermatol Res Pract"},{"key":"1008_CR57","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.77542","volume":"56","author":"P Mukhopadhyay","year":"2011","unstructured":"Mukhopadhyay P. Cleansers and their role in various dermatological disorders. Indian J Dermatol. 2011;56:2. https:\/\/doi.org\/10.4103\/0019-5154.77542.","journal-title":"Indian J Dermatol"},{"key":"1008_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27062010","volume":"27","author":"D Mijaljica","year":"2022","unstructured":"Mijaljica D, Spada F, Harrison IP. Skin cleansing without or with compromise: soaps and syndets. Molecules. 2022;27:2010. https:\/\/doi.org\/10.3390\/molecules27062010.","journal-title":"Molecules"},{"key":"1008_CR59","unstructured":"National Eczema Association (NEA). National Eczema Association\u2019s Seal of AcceptanceTM  [Internet]. 2025  [cited 2025 Jun 13]. https:\/\/nationaleczema.org\/eczema-products\/seal-home\/. Accessed 13 Jun 2025."},{"key":"1008_CR60","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/09546634.2020.1789050","volume":"33","author":"SG Danby","year":"2022","unstructured":"Danby SG, Draelos ZD, Gold LFS, Cha A, Vlahos B, Aikman L, et al. Vehicles for atopic dermatitis therapies: more than just a placebo. J Dermatol Treat. 2022;33:685\u201398. https:\/\/doi.org\/10.1080\/09546634.2020.1789050.","journal-title":"J Dermatol Treat"},{"key":"1008_CR61","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s43440-023-00510-3","volume":"75","author":"V Kakkar","year":"2023","unstructured":"Kakkar V, Saini K, Singh KK. Challenges of current treatment and exploring the future prospects of nanoformulations for treatment of atopic dermatitis. Pharmacol Rep. 2023;75:1066\u201395. https:\/\/doi.org\/10.1007\/s43440-023-00510-3.","journal-title":"Pharmacol Rep"},{"key":"1008_CR62","doi-asserted-by":"publisher","first-page":"252","DOI":"10.5114\/ada.2017.67848","volume":"3","author":"M Kot","year":"2017","unstructured":"Kot M, Bogaczewicz J, Kr\u0119cisz B, Wo\u017aniacka A. Contact allergy in the population of patients with chronic inflammatory dermatoses and contact hypersensitivity to corticosteroids. Adv Dermatol Allergol. 2017;3:252\u20139. https:\/\/doi.org\/10.5114\/ada.2017.67848.","journal-title":"Adv Dermatol Allergol"},{"key":"1008_CR63","first-page":"337","volume":"103","author":"SK Stacey","year":"2021","unstructured":"Stacey SK, McEleney M. Topical corticosteroids: choice and application. Am Fam Physician. 2021;103:337\u201343.","journal-title":"Am Fam Physician"},{"key":"1008_CR64","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1038\/jid.2009.133","volume":"129","author":"MJ Cork","year":"2009","unstructured":"Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129:1892\u2013908. https:\/\/doi.org\/10.1038\/jid.2009.133.","journal-title":"J Invest Dermatol"},{"key":"1008_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105341","author":"MA Pemberton","year":"2023","unstructured":"Pemberton MA, Kimber I. Propylene glycol, skin sensitisation and allergic contact dermatitis: a scientific and regulatory conundrum. Regul Toxicol Pharmacol. 2023. https:\/\/doi.org\/10.1016\/j.yrtph.2023.105341.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1008_CR66","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/cea.12760","volume":"46","author":"E Wenande","year":"2016","unstructured":"Wenande E, Garvey LH. Immediate\u2010type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46:907\u201322. https:\/\/doi.org\/10.1111\/cea.12760.","journal-title":"Clin Exp Allergy"},{"key":"1008_CR67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/DER.0000000000000307","volume":"29","author":"MA McGowan","year":"2018","unstructured":"McGowan MA, Scheman A, Jacob SE. Propylene glycol in contact dermatitis: a systematic review. Dermatitis. 2018;29:6\u201312. https:\/\/doi.org\/10.1097\/DER.0000000000000307.","journal-title":"Dermatitis"},{"key":"1008_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/DER.0000000000000315","volume":"29","author":"SE Jacob","year":"2018","unstructured":"Jacob SE, Scheman A, McGowan MA. Propylene glycol. Dermatitis\u00ae. 2018;29:3\u20135. https:\/\/doi.org\/10.1097\/DER.0000000000000315.","journal-title":"Dermatitis\u00ae"},{"key":"1008_CR69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jamadermatol.2022.5991","volume":"159","author":"MJ Reeder","year":"2023","unstructured":"Reeder MJ, Warshaw E, Aravamuthan S, Belsito DV, Geier J, Wilkinson M, et al. Trends in the prevalence of Methylchloroisothiazolinone\/Methylisothiazolinone contact allergy in North America and Europe. JAMA Dermatol. 2023;159:267. https:\/\/doi.org\/10.1001\/jamadermatol.2022.5991.","journal-title":"JAMA Dermatol"},{"key":"1008_CR70","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.anai.2018.07.008","volume":"121","author":"PM Elias","year":"2018","unstructured":"Elias PM, Sugarman J. Does moisturizing the skin equate with barrier repair therapy? Ann Allergy Asthma Immunol. 2018;121:653-656.e2. https:\/\/doi.org\/10.1016\/j.anai.2018.07.008.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1008_CR71","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/bjd.21294","volume":"186","author":"AC Kendall","year":"2022","unstructured":"Kendall AC, Nicolaou A. Topical application of lipids to correct abnormalities in the epidermal lipid barrier. Br J Dermatol. 2022;186:764\u20135. https:\/\/doi.org\/10.1111\/bjd.21294.","journal-title":"Br J Dermatol"},{"key":"1008_CR72","unstructured":"Ference JD, Last AR. Choosing topical corticosteroids  [Internet]. 2009. www.aafp.org\/afpAmericanFamilyPhysician135."},{"key":"1008_CR73","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/cod.14477","volume":"90","author":"E Borg","year":"2024","unstructured":"Borg E, Munro D, Thoning H. The management of chronic hand eczema: a retrospective patient record review. Contact Dermatitis. 2024;90:365\u201371. https:\/\/doi.org\/10.1111\/cod.14477.","journal-title":"Contact Dermatitis"},{"key":"1008_CR74","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/ced\/llad161","volume":"48","author":"TS Brookes","year":"2023","unstructured":"Brookes TS, Barlow R, Mohandas P, Bewley A. Topical steroid withdrawal: an emerging clinical problem. Clin Exp Dermatol. 2023;48:1007\u201311. https:\/\/doi.org\/10.1093\/ced\/llad161.","journal-title":"Clin Exp Dermatol"},{"key":"1008_CR75","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jaad.2019.11.020","volume":"83","author":"JM Tran","year":"2020","unstructured":"Tran JM, Reeder MJ. When the treatment is the culprit: prevalence of allergens in prescription topical steroids and immunomodulators. J Am Acad Dermatol. 2020;83:228\u201330. https:\/\/doi.org\/10.1016\/j.jaad.2019.11.020.","journal-title":"J Am Acad Dermatol"},{"key":"1008_CR76","first-page":"5","volume":"16","author":"M Al Jasser","year":"2011","unstructured":"Al Jasser M, Mebuke N, de Gannes GC. Propylene glycol: an often unrecognized cause of allergic contact dermatitis in patients using topical corticosteroids. Skin Therapy Lett. 2011;16:5\u20137.","journal-title":"Skin Therapy Lett"},{"key":"1008_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-016-0596-7","volume":"16","author":"IM Otani","year":"2016","unstructured":"Otani IM, Banerji A. Immediate and delayed hypersensitivity reactions to corticosteroids: evaluation and management. Curr Allergy Asthma Rep. 2016;16:18. https:\/\/doi.org\/10.1007\/s11882-016-0596-7.","journal-title":"Curr Allergy Asthma Rep"},{"key":"1008_CR78","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/CCID.S163814","volume":"12","author":"BB Johnson","year":"2019","unstructured":"Johnson BB, Franco AI, Beck LA, Prezzano JC. Treatment resistant atopic dermatitis: challenges and solution. Clin Cosmet Investig Dermatol. 2019;12:181\u201392. https:\/\/doi.org\/10.2147\/CCID.S163814.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1008_CR79","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","volume":"80","author":"J Peppers","year":"2019","unstructured":"Peppers J, Paller AS, Maeda-Chubachi T, Wu S, Robbins K, Gallagher K, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80:89-98.e3. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.047.","journal-title":"J Am Acad Dermatol"},{"key":"1008_CR80","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1600-0536.2007.01314.x","volume":"58","author":"S Schliemann","year":"2008","unstructured":"Schliemann S, Kelterer D, Bauer A, John SM, Skudlik C, Schindera I, et al. Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis. 2008;58:299\u2013306. https:\/\/doi.org\/10.1111\/j.1600-0536.2007.01314.x.","journal-title":"Contact Dermatitis"},{"key":"1008_CR81","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2500\/aap.2006.27.2915","volume":"27","author":"ML Pacor","year":"2006","unstructured":"Pacor ML, Di Lorenzo G, Martinelli N, Mansueto P, Friso S, Pellitteri ME, et al. Tacrolimus ointment in nickel sulphate\u2013induced steroid-resistant allergic contact dermatitis. Allergy Asthma Proc. 2006;27:527\u201331. https:\/\/doi.org\/10.2500\/aap.2006.27.2915.","journal-title":"Allergy Asthma Proc"},{"key":"1008_CR82","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000297524","volume":"221","author":"M Hordinsky","year":"2010","unstructured":"Hordinsky M, Fleischer A, Rivers JK, Poulin Y, Belsito D, Hultsch T. Efficacy and safety of pimecrolimus cream 1% in mild-to-moderate chronic hand dermatitis: a randomized, double-blind trial. Dermatology. 2010;221:71\u20137. https:\/\/doi.org\/10.1159\/000297524.","journal-title":"Dermatology"},{"key":"1008_CR83","unstructured":"Schliemann S, Pinter A, Schuttelaar M, Serra-Baldrich E, Baranowski K, Korn S, et al. Efficacy and safety of delgocitinib cream in adults with moderate-to-severe chronic hand eczema: results of the Phase 3 DELTA 1 trial. In: Eur Acad Dermatol Venereol (EADV) Congress. Berlin, Germany; 2023."},{"key":"1008_CR84","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","volume":"404","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404:461\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(24)01027-4.","journal-title":"Lancet"},{"key":"1008_CR85","doi-asserted-by":"crossref","unstructured":"Bauer A, Schuttelaar M-L, Baranowski K, Plohberger U, S\u00f8rensen L, Worm M. Delgocitinib cream reduces itch and pain in adults with moderate to severe chronic hand eczema: pooled analyses of the Phase 3 DELTA-1 and -2 trials. Am Acad Dermatol. 2024;91(3):AB174.","DOI":"10.1016\/j.jaad.2024.07.694"},{"key":"1008_CR86","unstructured":"Armstrong A, Bernier C, Bissonnette R, Chovatiya R, Magnolo N, Toth D, et al. Super responders\u201d following treatment with delgocitinib cream 20mg\/g in a subgroup of patients with moderate to severe chronic hand eczema. In: Am Acad Dermatol Annual Meeting. Orlando, Florida; 2025."},{"key":"1008_CR87","doi-asserted-by":"crossref","unstructured":"Gim\u00e9nez-Arnau A, Pinter A, Sondermann W, Reguiai Z, Woolf R, Lynde C, et al. Abstract N\u00b0: 7986 DELTA FORCE trial: a 24-week head-to-head phase 3 trial comparing the efficacy and safety of topical delgocitinib cream with oral alitretinoin capsules in adults with severe chronic hand eczema. In: Eur Acad Dermatol Venereol. Amsterdam; 2024.","DOI":"10.1016\/S0140-6736(25)00001-7"},{"key":"1008_CR88","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40257-022-00748-2","volume":"24","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Ruxolitinib cream 1.5%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol. 2023;24:143\u201351. https:\/\/doi.org\/10.1007\/s40257-022-00748-2.","journal-title":"Am J Clin Dermatol"},{"key":"1008_CR89","doi-asserted-by":"crossref","unstructured":"Zirwas M, Halden P, Lai Z, Kuo Y, Nawaz H, Stein Gold LF. Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: top-line results from a 16-week, multicenter, randomized, double-blind study. In: Fall Clinical Dermatology Conference. Las Vegas, NV, USA; 2024.","DOI":"10.25251\/skin.8.supp.500"},{"key":"1008_CR90","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1097\/DER.0000000000000793","volume":"32","author":"JS Kahn","year":"2021","unstructured":"Kahn JS, Grossman-Kranseler JS, Zancanaro P, Griffiths D, Dumont N, Rosmarin D. Topical crisaborole in the treatment of atopic hand dermatitis: a retrospective chart review. Dermatitis. 2021;32:e141\u20133. https:\/\/doi.org\/10.1097\/DER.0000000000000793.","journal-title":"Dermatitis"},{"key":"1008_CR91","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamadermatol.2024.3121","volume":"160","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Eichenfield LF, Alonso-Llamazares J, Draelos ZD, Ferris LK, Forman SB, et al. Roflumilast cream, 0.15%, for atopic dermatitis in adults and children. JAMA Dermatol. 2024;160:1161. https:\/\/doi.org\/10.1001\/jamadermatol.2024.3121.","journal-title":"JAMA Dermatol"},{"key":"1008_CR92","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/12034754231188325","volume":"27","author":"JSS Ho","year":"2023","unstructured":"Ho JSS, Molin S. A review of existing and new treatments for the management of hand eczema. J Cutan Med Surg. 2023;27:493\u2013503. https:\/\/doi.org\/10.1177\/12034754231188325.","journal-title":"J Cutan Med Surg"},{"key":"1008_CR93","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/09546630410027814","volume":"15","author":"GL Capella","year":"2004","unstructured":"Capella GL, Fracchiolla C, Frigerio E, Altomare G. A controlled study of comparative efficacy of oral retinoids and topical betamethasone\/salicylic acid for chronic hyperkeratotic palmoplantar dermatitis. J Dermatolog Treat. 2004;15:88\u201393. https:\/\/doi.org\/10.1080\/09546630410027814.","journal-title":"J Dermatolog Treat"},{"key":"1008_CR94","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol  [Internet]. 2024;90:e43-56. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.102.","journal-title":"J Am Acad Dermatol [Internet]"},{"key":"1008_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.049","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Agner T, Taylor JS, Molin S, Guttman-Yassky E. Hand eczema. Part 2: prevention, management, and treatment. J Am Acad Dermatol  [Internet]. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.049.","journal-title":"J Am Acad Dermatol [Internet]"},{"key":"1008_CR96","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jaad.2023.04.027","volume":"89","author":"PA Jimenez","year":"2023","unstructured":"Jimenez PA, Sofen HL, Bissonnette R, Lee M, Fowler J, Zammit DJ, et al. Oral spleen tyrosine kinase\/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: results of a randomized phase 2 study. J Am Acad Dermatol. 2023;89:235\u201342. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.027.","journal-title":"J Am Acad Dermatol"},{"key":"1008_CR97","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jaad.2023.12.066","volume":"90","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Worm M, Honari G, Masuda K, Sygu\u0142a E, et al. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024;90:1190\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2023.12.066.","journal-title":"J Am Acad Dermatol"},{"key":"1008_CR98","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy. J Eur Acad Dermatol Venereol. 2022;36:1409\u201331. https:\/\/doi.org\/10.1111\/jdv.18345.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1008_CR99","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/jdv.18429","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema\u2014part II: non\u2010systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36:1904\u201326. https:\/\/doi.org\/10.1111\/jdv.18429.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1008_CR100","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/cod.13459","volume":"82","author":"K Politiek","year":"2020","unstructured":"Politiek K, Ofenloch RF, Angelino MJ, van den Hoed E, Schuttelaar MLA. Quality of life, treatment satisfaction, and adherence to treatment in patients with vesicular hand eczema: a cross\u2010sectional study. Contact Dermatitis. 2020;82:201\u201310. https:\/\/doi.org\/10.1111\/cod.13459.","journal-title":"Contact Dermatitis"},{"key":"1008_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004055.pub2","author":"WA Christoffers","year":"2019","unstructured":"Christoffers WA, Coenraads P-J, Svensson \u00c5, Diepgen TL, Dickinson-Blok JL, Xia J, et al. Interventions for hand eczema. Cochrane Database Syst Rev  [Internet]. 2019. https:\/\/doi.org\/10.1002\/14651858.CD004055.pub2.","journal-title":"Cochrane Database Syst Rev [Internet]"},{"key":"1008_CR102","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16855","volume":"179","author":"D Brass","year":"2018","unstructured":"Brass D, Fouweather T, Stocken DD, Macdonald C, Wilkinson J, Lloyd J, et al. Hand eczema phototherapy pilot trial. Br J Dermatol. 2018;179:e64. https:\/\/doi.org\/10.1111\/bjd.16855.","journal-title":"Br J Dermatol"},{"key":"1008_CR103","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S87987","author":"A Patrizi","year":"2015","unstructured":"Patrizi A, Raone B, Ravaioli GM. Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol. 2015. https:\/\/doi.org\/10.2147\/CCID.S87987.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1008_CR104","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad113","author":"M Wittmann","year":"2023","unstructured":"Wittmann M, Smith I, Brown S, Berekmeri A, Vargas-Palacios A, Sunderland L, et al. 006 Comparison of alitretinoin vs. psoralen plus ultraviolet A as first-line treatments for chronic severe hand eczema: results from the ALPHA trial. Br J Dermatol  [Internet]. 2023. https:\/\/doi.org\/10.1093\/bjd\/ljad113.","journal-title":"Br J Dermatol [Internet]"},{"key":"1008_CR105","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1046\/j.1365-2133.2001.04078.x","volume":"144","author":"CG Mortz","year":"2001","unstructured":"Mortz CG, Lauritsen JM, Bindslev-Jensen C, Andersen KE. Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis. Br J Dermatol. 2001;144:523\u201332. https:\/\/doi.org\/10.1046\/j.1365-2133.2001.04078.x.","journal-title":"Br J Dermatol"},{"key":"1008_CR106","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/cod.13727","volume":"84","author":"AB Simonsen","year":"2021","unstructured":"Simonsen AB, Ruge IF, Quaade AS, Johansen JD, Thyssen JP, Zachariae C. Increased occurrence of hand eczema in young children following the Danish hand hygiene recommendations during the COVID\u201019 pandemic. Contact Dermatitis. 2021;84:144\u201352. https:\/\/doi.org\/10.1111\/cod.13727.","journal-title":"Contact Dermatitis"},{"key":"1008_CR107","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jdin.2023.02.008","volume":"11","author":"MA Haft","year":"2023","unstructured":"Haft MA, Park HH, Lee SS, Sprague JM, Eichenfield LF. Pediatric chronic hand eczema: epidemiology, clinical presentation, and management. JAAD Int. 2023;11:165\u201373. https:\/\/doi.org\/10.1016\/j.jdin.2023.02.008.","journal-title":"JAAD Int"},{"key":"1008_CR108","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjd.19818","volume":"185","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Warshaw EM, Maibach HI, DeKoven JG, Taylor JS, Atwater AR, et al. Hand eczema in children referred for patch testing: North American Contact Dermatitis Group Data, 2000\u20132016*. Br J Dermatol. 2021;185:185\u201394. https:\/\/doi.org\/10.1111\/bjd.19818.","journal-title":"Br J Dermatol"},{"key":"1008_CR109","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40272-023-00574-x","volume":"25","author":"MA Haft","year":"2023","unstructured":"Haft MA, Park HH, Lee SS, Sprague JM, Paller AS, Cotton CH, et al. Diagnosis and management of pediatric chronic hand eczema: The PeDRA CACHES survey. Pediatr Drugs. 2023;25:459\u201366. https:\/\/doi.org\/10.1007\/s40272-023-00574-x.","journal-title":"Pediatr Drugs"},{"key":"1008_CR110","unstructured":"Andrus E. DELTA TEEN Highlights Potential of delgocitinib in adolescents with chronic hand eczema  [Internet]. Dermatol Times. 2025  [cited 2025 Aug 8]. https:\/\/www.dermatologytimes.com\/view\/delta-teen-highlights-potential-of-delgocitinib-in-adolescents-with-chronic-hand-eczema. Accessed 8 Aug 2025."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01008-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01008-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01008-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T11:19:45Z","timestamp":1774696785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01008-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1008"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01008-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,8]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state the following conflicts of interest: AA has served as a research investigator, scientific advisor, or speaker to AbbVie, Arcutis, BI, BMS, Leo, UCB, Janssen, Lilly, Novartis, Ortho, Sun, Dermavant, Sanofi, Takeda, Regeneron, and Pfizer. CGB has served as an investigator for AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Timber, and Palvella; a consultant for AbbVie, Almirall, Amgen, Apogee, Arcutis, Botanix, Connect BioPharma, Dermavant, Eli Lilly, EPI Health\/Novan, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, Teladoc, Triveni, and UCB. RC has served as an advisor, consultant, speaker, and\/or investigator for AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics Inc., Argenx, Astria Therapeutics Inc., Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celldex CLn Skin Care, Dermavant, Eli Lilly and Company, EMD Serono, Formation Bio, Galderma, Genentech, GSK, Incyte, Johnson & Johnson, Kenvue, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio, UCB, Zai Lab. RC is an Editorial Board member of American Journal of Clinical Dermatology. RC was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. DC has acted as a consultant for, and received honorarium from Cosmetic Ingredient Review (CIR), Dualitas, Ferndale Laboratories,\u00a0FIDE, Leo, Medimetriks  [past], and UCB. He has had stock or stock options in Evommune, Timber  [past], and has sat on the Board of\u00a0Directors for Evommune and Timber  [past]. BDE has served as a consultant and\/or clinical study investigator for AbbVie, Acelyrin, Allakos, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Bristol-Myers Squibb, Celldex, Concert Pharma, DermBiont, Dermavant Sciences, Eli Lilly, Evelo Biosciences, Evommune, Incyte, Janssen, Kymab, LEO Pharma, Navigator Medicines, Novartis, Pfizer, Oruka, Priovant, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, UCB Pharma and Ventyx, and as a paid speaker for Bristol-Myers Squibb, Dermavant, Incyte, LEO Pharma, Eli Lilly, Regeneron, Sanofi Genzyme and UCB Pharma. LFE has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, CorEvitas, Dermavant, Eli Lilly, Forte, Galderma, Incyte Corporation, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Target RWE, T-Rex, and UCB. EGY is an employee of Mount Sinai and has received research grants (paid to the institution) from: Regeneron, Sanofi, Eli Lilly, Galderma, Leo Pharma, Pfizer, Amgen, GSK, Incyte, Sanofi, Bristol Meyers Squibb, Arcutis, AnaptysBio, Inmagene, Abbvie, Xencor, Q32 Bio, Opsidio, Apollo Therapeutics, Aclaris Therapeutics, Concerto Biosciences. EGY is also a consultant for: Abbvie, Aclaris Therapeutics, Almirall, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics, Arcutis, Artax Biopharma, Astria, Boerhinger-Ingelhiem, Bristol Meyers Squibb, Celldex, Centrexion Therapeutics, Connect Biopharm, Coty, DBV, Dualitas Therapeutics, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals, Galderma, Gate Bio, GSK Immunology, Incyte, Inmagene, Janssen Biotech, Jasper Therapeutics, Kymera Therapeutics, Kyowa Kirin, Leo Pharma, Matchpoint Therapeutics, Merck, Nektar Therapeutics, NUMAB Therapeutics, OTSUKA, Pfizer, Pharmaxis, Proteologix, RAPT, RayThera, Regeneron, Ribon Therapeutics, Sanofi, SATO, Schr\u00f6dinger, Sitryx, Sun Pharma, Takeda, Teva, TRex Bio, UCB, VRG Therapeutics. JIS has received honoraria as a consultant and\/or advisory board member for Abbvie, Aldena, Aldena, Amgen, AObiome, Apollo, Arcutis, Arena, Asana, Aslan, Attovia, Bodewell, Boehringer-Ingelheim, Bristell-Meyers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Eli Lilly, FIDE, Formation Bio, Galderma, GlaxoSmithKline, Incyte, Inmagene, Invea, Kiniksa, Leo Pharma, Merck, Nektar, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sandoz, Sanofi-Genzyme, Shaperon, TARGET-RWE, Teva, Triveni, UCB, Union, UpToDate; speaker for Abbvie, Arcutis, Dermavant, Eli Lilly, Galderma, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme; institution received grants from Galderma, Incyte, Pfizer. ELS reports personal fees from AbbVie, Amgen, Arcutis, Areteia Therapeutics, Astria Therapeutics, Bristol Myers Squibb \u2013 BMS, CorEvitas, Corvus, Dermira, Eli Lilly, Evelo Biosciences, Evomunne, FIDE, Forte Bio RX, Galderma, GlaxoSmithKline, Gilead Sciences, Impetus Healthcare, Incyte, Innovaderm Reche, Janssen, Johnson & Johnson, Kyowa Kirin Pharmaceutical Development, LectureLinx (LLX), Leo, Merck, NUMAB Therapeutics AG, Pfizer, Physicians World LLC, PRImE, Recludix Pharma, Regeneron, Roche Products Ltd, Roivant, Sanofi-Genzyme, SITRYX Therapeutics, Trevi therapeutics, Valeant.\u00a0ELS reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Incyte, Lilly, Kymab, Kyowa Kirin, National Jewish Health, Leo, Pfizer, Regeneron, Sanofi, Target, VeriSkin. WSB reports advisory board fees (paid to institution) from Pfizer, Amgen, Sanofi, research Grants (paid to institution) from Pfizer, and speaker fees (paid to institution) from Arcutis, Galderma. LSG reports investigator, consultant and\/or speaker for Abbvie, Amgen, Arcutis,Galderma, Incyte,Leo,Lilly,Pfizer, Regeneron, Sanofi JY has served as a consultant\/advisory board\/investigator for the following: Abbvie, Arcutis, Astria, Dermavant, iRhythm, Kiehl\u2019s\/L\u2019Oreal, Leo, Lilly, National Eczema Association, O\u2019Glacee, Pfizer, Sanofi, Smartpractice, Sol-Gel. He also receives honorarium from UptoDate and BMJ Best Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"All views expressed by the authors are those of the individual and do not represent those of their organization\/place of work. Contributors  [AA, CB, RC, DC, BE, LE, EG, JS, ES, WSB, LSG, JY] agreed the design of the manuscript and the content. All authors contributed to the development of the manuscript wireframe and subsequent drafts. All authors approved the work before submission, and again after peer review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}